Review of NICE Technology Appraisal Guidance No 82; Pimecrolimus and tacrolimus for atopic eczema

The Institute was proposing that the original guidance become static and would not be updated.

Guidance is placed on the static list when it is clear that there is no new research available that would have any material effect on the current guidance.  After consideration of all of the comments the Institute’s Guidance Executive has decided to proceed with the proposal. We will therefore move this guidance to the static list. Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.